It would be nice to know what they’re thinking as far as ‘commercial opportunity’ goes. Possible partnership for this pillar? With the admission of recent approaches in this space in the 4C hopefully something decent is brewing.
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |